The prevalence of dementia would be reduced by 50% if risk reduction strategies were successful in delaying its onset by 5 years (Jorm et al., 1987). In this article we describe the potential for prevention of dementia. Our review does not attempt to be exhaustive: for example, we do not discuss the role of oestrogen or vaccines for Alzheimer’s disease. Instead, we focus on a few key areas that are particularly amenable to potential therapeutic intervention, giving possible pathophysiological mechanisms and a flavour of the available evidence.

Prevention strategies may be empirically grouped into three categories (although a crossover between categories is expected): treatment of vascular risk factors, neuroprotection and building up neuronal reserves. Each of the three categories includes a number of strategies relating to specific risk factors or mechanisms involved in neurodegeneration (Box 1).

### Treatment of vascular risk factors

#### Hypertension

Hypertension is a known risk factor for stroke, both haemorrhagic and ischaemic, which itself increases the risk of dementia by five to ten times. Hypertension can cause hyalinisation of vessel walls, reducing cerebral blood flow and causing ischaemia in vulnerable areas such as deep white matter. This can result in the disconnection of subcortical–cortical association pathways, which is one of the likely mechanisms that lead to cognitive impairment. Hypertension is also thought to disrupt the blood–brain barrier, exposing the brain to systemic factors.

Several large epidemiological studies have now established hypertension (both systolic and diastolic) in middle age as a risk factor for Alzheimer’s disease and vascular dementia in later life.

---

Nitin Purandare is a senior lecturer and honorary consultant in old age psychiatry at the University of Manchester and Manchester Mental Health and Social Care Trust (University of Manchester, School of Psychiatry and Behavioural Sciences, 2nd Floor, Education and Research Centre, Wythenshawe Hospital, Manchester M23 9LT, UK. Tel: 0161 291 5887; fax: 0161 291 5882; e-mail: nitin.purandare@man.ac.uk). His main research interest is in the vascular aetiology of dementia. Clive Ballard is Professor of Old Age Psychiatry at King’s College, London. He was recently appointed Director of Research at the Alzheimer’s Society. Alistair Burns is Professor of Old Age Psychiatry and Head of the School of Psychiatry and Behavioural Sciences at the University of Manchester. He was President of the International Psychogeriatric Association between 2001 and 2003.
life. For example, an ageing study that followed over 3500 Japanese American men over 25 years found hypertension to increase the risk of dementia four- to fivefold in those who had not been treated with antihypertensives. The risk was found to be greatest in those with systolic hypertension and the apolipoprotein E4 (ApoE4) allele (after controlling for other risk factors; odds ratio, OR = 13.0) (Launer et al, 2000). Murray et al (2002) followed 1900 African Americans over 5 years and found the use of antihypertensives to be associated with a 38% (OR = 0.62) reduction in incident Alzheimer’s disease and vascular dementia.

The results of randomised controlled trials (RCTs) studying the use of antihypertensives in individuals with hypertension have been variable. Earlier trials identified no significant impact of such drugs on cognition or incident dementia. The more recent Systolic Hypertension in Europe (Syst-Eur) study (Forette et al, 2003) reported that niitrendipine (a calcium channel blocker) reduced the risk of Alzheimer’s disease by 50% over 2 years. The results of RCTs involving people with multiple vascular risk factors in addition to hypertension have been more consistently encouraging. For example, the PROGRESS (Tzourio et al, 2003) trial found a significant reduction of incident dementia in patients who had had strokes treated with an angiotensin-converting enzyme (ACE) inhibitor. The statistical power of these studies is limited by the low incident risk of dementia in the study populations.

In all RCTs, incident dementia has been a secondary outcome, heart disease or stroke being the primary outcomes. The time lapse between the diagnosis of hypertension and onset of dementia can be over 15 years, and it is not known whether the protective effect on incident dementia of starting antihypertensives extends throughout this period. In this respect, it is interesting to note that blood pressure falls just before or at the onset of dementia, probably because of the central dysregulation of blood pressure control. In hypertensive patients with multi-infarct dementia, maintaining systolic blood pressure within the upper limits of normal (135–150 mmHg) was more beneficial in preserving cognitive function than reducing systolic blood pressure below this level (Meyer et al, 1986).

Another issue that needs further clarification is whether the risk reduction is related to actual reduction in blood pressure and/or some other neuroprotective action of the individual anti-hypertensive agent (e.g. a calcium channel antagonist or ACE inhibitor). For example, angiotensin II inhibits acetylcholine release and angiotensin II (AT1) receptor blockers improve cognitive performance (Barnes et al, 1990; Fogari et al, 2003).

### Hypercholesterolaemia

Hypercholesterolaemia, especially in the form of increased low-density lipoproteins, is a known risk factor for coronary heart disease, atherosclerosis and stroke, which are all associated with increased risk of dementia. The ApoE4 allele, the best established genetic risk factor for Alzheimer’s disease, affects stabilisation of membrane lipoproteins and is now known to be a risk factor for hypercholesterolaemia. Cholesterol increases the production of β-amyloid, which is at the centre of senile plaques in Alzheimer’s disease. Lipid-lowering agents reduce cholesterol but lack the additional benefits of statins. Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA). In addition, statins have an antioxidant action, decrease pro-inflammatory processes and improve cerebral blood flow. They have also been shown to reduce amyloid β-protein 42 (Aβ42) in hippocampal neurons and cerebrospinal fluid.

Moroney et al (1999) followed up more than 2000 older people in New York over 2 years and found those with cholesterol levels in the highest quartile to be at increased risk of dementia, especially vascular dementia (OR = 3–4), compared with those in the lowest quartile. A Finnish study of a similar size but with a much longer follow-up (21 years) reported that raised cholesterol in middle age (≥6.5 mmol/l) more than doubled the risk of dementia, including Alzheimer’s disease, independently of other risk factors such as hypertension and ApoE4 (Kivipelto et al, 2002).

Review of case-control and retrospective cohort studies indicates that statins reduce the risk of dementia, but there are some important inconsistencies between individual reports. For example, some studies have found risk reduction with lipid-lowering agents in general; others suggest the risk reduction to be more specifically associated with the use of statins. A meta-analysis of seven observational studies found risk reduction in cognitive impairment to be significant for statins (OR = 0.43) but not for other lipid-lowering agents (Eminan et al, 2003). The results of intervention studies examining the effect of statins on cognitive functioning have, however, not been encouraging. Neither simvastatin (Heart Protection Study Collaborative Group, 2002) nor pravastatin (Shepherd et al, 2002) were shown to have any positive effect on cognitive decline. Not all statins are the same, and whether individual statins would have a differential effect on cognition is not known. In this respect, it is noteworthy that simvastatin and lovastatin, but not mevastatin or pravastatin, significantly inhibit butyrylcholinesterase. In rare cases, statins have an...
adverse effect on cognition, although the underlying mechanism and causality are not certain (Wagstaff et al., 2003).

**Diabetes**

Diabetes is a known risk factor for cerebrovascular disease. Insulin receptors are abundant in the brain. Amyloid β-protein 42 reduces insulin binding, which may partially explain the insulin resistance observed in Alzheimer’s disease. Insulin reduces amyloid precursor protein and β-amyloid in Alzheimer’s disease, especially in those not carrying the ApoE4 allele.

Large epidemiological studies from the USA, Canada and The Netherlands, involving over 17,000 people followed for between 2 and 5 years, have shown diabetes to increase the risk of both Alzheimer’s disease and vascular dementia (OR = 2–4), independent of other risk factors. Diabetes may be a stronger risk factor for vascular dementia in general and for Alzheimer’s disease in ApoE4-negative individuals in particular, but this needs further confirmation. Whether treatment of diabetes can reduce the risk of dementia is unknown. A Cochrane review identified five trials in this field, but none was suitable for inclusion as each was either not double-blind or did not include both pre- and post-treatment cognitive measures (Areosa & Grimley, 2002).

**Carotid atherosclerosis**

Hypertension, hypercholesterolaemia, diabetes and smoking are known risk factors for carotid atherosclerosis. Atherosclerosis of carotid arteries is a major determinant of stroke, and the latter increases the risk of dementia five- to tenfold. The mechanism involved is thought to be ischaemia or embolism of a large thrombus. In our pilot study, spontaneous cerebral emboli were detected in 11/41 (27.5%) individuals with dementia, compared with 1/16 (7%) controls. Emboli were most frequent in vascular dementia (7/17, 41%) compared with controls (P = 0.04) (Purandare et al., 2005). We found no relationship between the presence of spontaneous cerebral emboli and carotid disease (probably because of the small sample size), but as most people with severe carotid stenosis are likely to produce spontaneous cerebral emboli (Hutchinson et al., 2002), it is possible that repeated subclinical microembolisation of cerebral circulation may be another mechanism of brain damage in patients with carotid disease.

Hofman et al. (1997), in their population-based study involving 284 individuals with dementia (207 with Alzheimer’s disease) and 1698 controls, found both Alzheimer’s disease and vascular dementia to be associated with the presence of carotid atherosclerosis. In participants with severe atherosclerosis (compared with those without atherosclerosis), the odds ratios for Alzheimer’s disease and vascular dementia were 3.0 (95% CI 1.5–6.0) and 9.5 (95% CI 3.0–30.0) respectively. Whether controlling spontaneous cerebral emboli in patients with moderate-to-severe carotid atherosclerosis will delay cognitive decline is not known.

**Heart disease**

Myocardial infarction and atrial fibrillation are known risk factors for both Alzheimer’s disease and vascular dementia. Senile plaques are more common in people with severe cardiovascular disease than in those without a history of heart disease. A prospective cohort study with up to 7-year follow-up found older women with a history of myocardial infarction to be at five times greater risk of developing dementia (Aronson et al., 1990). Similarly, a population-based cohort study found atrial fibrillation to double the risk of all dementia, independent of clinical stroke (Ott et al., 1997).

**Smoking**

Smoking, an established cardiovascular risk factor, is considered to be one of the prime targets in prevention of vascular cognitive impairment and vascular dementia. An aging study of elderly Japanese American men found that smoking during middle age was associated with later risk of cognitive impairment, and that the risk was higher for those who continued to smoke into old age than it was for those who no longer smoked (Galanis et al., 1997). Smoking is also a risk factor for Alzheimer’s disease, and current smoking has been shown to double the incidence of dementia and Alzheimer’s disease (Ott et al., 1998). In contrast, some epidemiological reviews suggest that smoking may be protective against Alzheimer’s disease, but this finding might be attributable to the underappreciated influence of differential survival. Although smoking appears overall to be associated with a doubling of the risk of Alzheimer’s disease (presumably because of cardiovascular factors), nicotine itself may have neuroprotective properties, possibly reducing amyloid burden (Nordberg et al., 2002).

**Neuroprotection**

**Folate and vitamin B12**

Folate and vitamin B12 are required both in the methylation of homocysteine to methionine and in
the synthesis of S-adenosylmethionine, a methyl donor. Hyperhomocysteinaemia damages vascular endothelium and is an independent risk factor for coronary artery disease, peripheral vascular disease and cerebrovascular disease, especially extracranial carotid atherosclerosis. In addition, metabolites of homocysteine have an excitotoxic effect on N-methyl-
D-aspartate (NMDA) receptors. An elevated homocysteine level is a more accurate marker of folate or vitamin B12 deficiency at tissue level than are serum folate or vitamin B12 levels. Hyperhomocysteinaemia is common in older people, and is present in about 30% of individuals with mild cognitive impairment, 45% of those with Alzheimer’s disease and 60% of those with vascular dementia.

In older people without dementia, elevated plasma homocysteine is associated with some indicators of cognitive impairment. Dufouil et al (2003) followed 1241 people aged between 61 and 73 years over a 4-year period. They found an association between higher concentrations of homocysteine and impaired neuropsychological performance, with the odds of cognitive decline 2.8-fold \((P<0.05)\) higher in individuals with homocysteine levels above 15 µmol/l compared with those with levels below 10 µmol/l.

Elevated total homocysteine is associated with Alzheimer’s disease and predicts radiological evidence of disease progression. A large epidemiological study in the USA, involving 1092 older people followed over 8 years, found that the risk of Alzheimer’s disease nearly doubled (relative risk 1.8, 95% CI 1.3–2.5) with an increase of one standard deviation in homocysteine levels at baseline (Seshadri et al, 2002).

Although an association between elevated homocysteine and cognitive impairment in Alzheimer’s disease has been found, the effect of reducing homocysteine levels on cognition and global functioning is not clear. A case–control study from Ireland found moderately high homocysteine levels to be associated with stroke, vascular dementia and Alzheimer’s disease, independent of vascular risk factors and nutritional status (Mclroy et al, 2002). A meta-analysis from the Homocysteine Studies Collaboration Group (2002), which included individual participant data from 30 prospective or retrospective studies, found that after adjusting for known cardiovascular risk factors, low homocysteine levels \((3.0 \text{ (s.d. } = 0.41) \mu\text{mol/l})\) were associated with an 11% lower risk of ischaemic heart disease and a 19% lower risk of stroke. In a small prospective study involving 33 patients, Nilsson et al (2001) reported an improvement in cognitive function after 2 months of vitamin B12 or folate in individuals with mild-to-moderate dementia who had elevated homocysteine levels.

**Antioxidants (vitamins C and E, alcohol and green tea)**

*In vitro* studies suggest that ApoE4 reduces the antioxidant capacity of neurons. Oxidative stress can cause lipoprotein oxidation, β-amyloid polymerisation and generation of excessive free radicals. Vitamins C and E, along with alcohol (in moderation), scavenge these free radicals. Furthermore, micronutrients in red wine, especially resveratrol, have been shown to protect against β-amyloid toxicity, an effect also observed with green tea (Choi et al, 2001; Russo et al, 2003; Savaskan et al, 2003).

Low levels of vitamins C and E have been found in both the blood and cerebrospinal fluid of people with Alzheimer’s disease. Epidemiological evidence suggests that higher dietary intake of these vitamins is associated with lower risk of dementia. An RCT in which 341 people with moderate-to-severe Alzheimer’s disease were randomised to receive selegiline (a monoamine oxidase inhibitor) and vitamin E (either alone or in combination) or placebo found all active treatments, including vitamin E alone, to slow the progression of Alzheimer’s disease over 2 years, as measured by time to occurrence of death, institutionalisation, loss of ability to perform daily activities and quality of life. A large 5-year study in Sweden, involving 900 people for an average of 6 years, moderate alcohol consumption (1–3 drinks per day) was associated with reduced risk of dementia, including both Alzheimer’s disease and vascular dementia (relative risk RR = 0.58) (Ruitenbergen et al, 2002). Orgogozo et al (1997) found 250–500 ml of wine daily to reduce the risk of dementia even more \((OR = 0.19)\).

Additional studies are needed to examine the effect of type of alcohol on risk reduction.

**Anti-inflammatory agents**

The importance of inflammatory processes in causation of dementia is now well established, with evidence from biochemical, neuropathological and epidemiological studies. Primary inflammatory cytokines such as the interleukins IL-1β and IL-6 and α2-macroglobulin are increased in the brains of patients with Alzheimer’s disease. The neuropathological features of Alzheimer’s disease include accumulation of microglia and astrocytes around senile plaques. Both express human leukocyte antigens (HLAs) and are involved in activation of the complement cascade. These inflammatory changes are thought to lead to further amyloid deposition and neuronal damage. Non-steroidal anti-inflammatory drugs (NSAIDs) may offer a neuroprotective effect by inhibition of both cyclooxygenases COX-1 and COX-2. There are interesting
differences between locations and actions of COX-1 and COX-2, but all the epidemiological evidence is based on traditional NSAIDs with mixed action.

A number of epidemiological studies have shown long-term use of NSAIDs to be associated with a two- to fourfold reduced risk of Alzheimer’s disease, but others have been inconclusive. Int’Veld et al (2001) suggest that the conflicting evidence may be related to inaccurate recording and reliance on patients’ and/or relatives’ memory or incomplete medical records. They examined computerised pharmacy records in a follow-up study of almost 7000 residents of Rotterdam over 7 years. The study found use of NSAIDs to be associated with reduced risk of Alzheimer’s disease that depended on the duration of the use (<1 month: RR = 0.95; 1–24 months: RR = 0.83; >24 months: RR = 0.20). The results of intervention trials in Alzheimer’s disease have been disappointing. It may be that some NSAIDs influence amyloid deposition by inhibiting γ-secretase, independent of cyclo-oxygenase activity (Weggen et al, 2001). Ongoing trials are investigating the potential effects of such agents.

Building up neuronal reserves

Cognitive activity

A number of cross-sectional and retrospective studies have found an inverse relationship between cognitive activity and risk of dementia. The repetition of cognitive activities may improve processing functions such as working memory and perceptual speed or, with repetition, certain cognitive skills may become more efficient (possibly owing to an increased dendritic network) and less susceptible to the pathology of Alzheimer’s disease. On the other hand, cognitive activity may be a proxy for some other factors such as education and socioeconomic status. It is also possible that a reduction in cognitive activity may be an early consequence rather than a cause of dementia.

Wilson et al (2002) followed 801 older members of the clergy over 4 years. One-hundred and eleven developed Alzheimer’s disease. They recorded seven common activities that involved information processing as a core component (e.g. reading, watching the television and doing crosswords). The frequency of each activity was rated on a 5-point scale (1 = once a year, 5 = every day) and responses to each item were averaged to calculate a composite score (range: 1–5). After controlling for age, gender and education, a 1-point increase in cognitive activity was associated with a 33% reduction in risk of Alzheimer’s disease (RR = 0.67). A similar finding has emerged from other cohort studies, but there have been no RCTs.

Physical activity

The importance of exercise in cardiovascular risk reduction is already established. Physical exercise can also increase insulin-like growth factor (IGF-1), which has been shown to reduce τ-phosphorylation, a process implicated in Alzheimer’s disease.

No clinical studies have specifically examined the role of physical exercise in prevention of dementia. All epidemiological evidence relates to physical activity rather than physical exercise. Wilson et al (2002) suggested that risk reduction was due to cognitively stimulating activities rather than just physical activity, while Friedland et al (2001) found that reduced activity (whether intellectual or physical) in middle age increased the risk of developing Alzheimer’s disease by 250%. The mixed results could be partly explained by arbitrary division of activities into physical or cognitive categories. For example, dancing or going to a museum, included as cognitive activities by Wilson et al (2002), also include an strong physical component.

Social and leisure activity

Activities, either cognitive or physical, often include social aspects and are leisure pursuits. The social aspect of an activity or a rich social network in itself may be beneficial in reducing risk of dementia. Wang et al (2002) found that engagement in stimulating activities (mental, social or productive) reduced the risk of developing dementia over 6 years by 50% (RR = 0.54–0.58). In experiments on rats, environmental enrichment has been shown to inhibit spontaneous apoptosis, increase neurogenesis in the dentate gyrus and improve spatial memory (Nilsson et al, 1999; Young et al, 1999). This suggests a possible link between environment/social stimulation and regenerative brain processes.

Target populations

Dementia typically presents clinically in the sixth or seventh decade of life. However, a number of risk factors, such as hypertension and cholesterol in middle age (15–20 years earlier), are now known to be involved, suggesting that the disease process (e.g. amyloid deposition) may have continued at a subclinical level for a number of years before clinical presentation and diagnosis. Perhaps prevention strategies should therefore be targeted at middle-aged people who may not have any cognitive impairment. This may be economically impractical, as the actual number developing dementia would be small, requiring a very long follow-up. We would need better identification of subgroups at highest risk and surrogate markers of sub-clinical disease progression.
Advances in Psychiatric Treatment (2005), vol. 11. http://apt.rcpsych.org/

Table 1 Summary of epidemiological evidence for treatable risk factors in prevention of dementia

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Risk of dementia (OR or RR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension in middle age</td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>1.9–10.8</td>
</tr>
<tr>
<td>Diastolic</td>
<td>2.0–4.6</td>
</tr>
<tr>
<td>Hypercholesterolaemia in midlife</td>
<td>2.6–4.1</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.3–5.5</td>
</tr>
<tr>
<td>Carotid atherosclerosis</td>
<td>2.3–9.5</td>
</tr>
<tr>
<td>B12/folate deficiency</td>
<td>1.4–1.9</td>
</tr>
<tr>
<td>Vitamin C or E (per 1 standard deviation increase in use)</td>
<td>0.82</td>
</tr>
<tr>
<td>Alcohol (1–3 units per day)</td>
<td>0.19–0.58</td>
</tr>
<tr>
<td>Anti-inflammatory drugs (used for 2 or more years)</td>
<td>0.20</td>
</tr>
<tr>
<td>Cognitive or pleasurable activity (per 1 point increase in activity)</td>
<td>0.67–0.93</td>
</tr>
</tbody>
</table>

1. Odds ratio or relative risk.

Conclusions

The evidence from large cohort studies (Table 1) suggests that it is possible to prevent or delay onset of dementia, but evidence from RCTs is limited. Currently ongoing RCTs, which tend to focus on one or two vascular risk factors, may strengthen the evidence, although they do not focus on dementia as a primary outcome. There is a need for RCTs, preferably with incident dementia as a primary outcome, that target multiple risk factors in at-risk people with mild cognitive impairment. Such trials would need to be multi-centred and of sufficient duration, possibly requiring pooled resources from two or more funding bodies.

References


**MCQs**

1. **The following are preventable risk factors for dementia:**
   a. hypertension
   b. inactivity
   c. Apoe E4
   d. raised homocysteine
   e. age.

2. **Delaying onset of dementia by 5 years may reduce its prevalence by:**
   a. 10%
   b. 20%
   c. 30%
   d. 40%
   e. 50%.

3. **Homocysteine levels above 15 μmol/l increase the risk of developing cognitive impairment over 4 years by a factor of:**
   a. 1.8
   b. 2.8
   c. 3.8
   d. 4.8
   e. 5.8.
4 Reduced activities in middle age have been shown to increase risk of Alzheimer’s disease by:

   a  50%
   b  100%
   c  200%
   d  250%
   e  300%.

5 The annual conversion rate to dementia in patients with ‘mild cognitive impairment’ is:

   a  10%
   b  20%
   c  30%
   d  40%
   e  50%.

MCQ answers

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>a</td>
<td>F</td>
<td>a</td>
<td>F</td>
<td>a</td>
</tr>
<tr>
<td>b</td>
<td>T</td>
<td>b</td>
<td>F</td>
<td>b</td>
</tr>
<tr>
<td>c</td>
<td>F</td>
<td>c</td>
<td>F</td>
<td>c</td>
</tr>
<tr>
<td>d</td>
<td>T</td>
<td>d</td>
<td>F</td>
<td>d</td>
</tr>
<tr>
<td>e</td>
<td>F</td>
<td>e</td>
<td>T</td>
<td>e</td>
</tr>
</tbody>
</table>

The Royal College of Psychiatrists / Gaskell

are exhibiting and selling books at the

American Psychiatric Association Annual Meeting 2005

Atlanta, GA 21-26 May 2005

Come and see us in the
Book Fair at booth 2116

All delegates get 10% discount off books bought at the APA